NL8005252A - Dubbellaagstablet. - Google Patents
Dubbellaagstablet. Download PDFInfo
- Publication number
- NL8005252A NL8005252A NL8005252A NL8005252A NL8005252A NL 8005252 A NL8005252 A NL 8005252A NL 8005252 A NL8005252 A NL 8005252A NL 8005252 A NL8005252 A NL 8005252A NL 8005252 A NL8005252 A NL 8005252A
- Authority
- NL
- Netherlands
- Prior art keywords
- layer
- tablet
- active ingredient
- tablet according
- penicillanate
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- -1 pivaloyloxymethyl Chemical group 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- RBKMMJSQKNKNEV-RITPCOANSA-N penicillanic acid Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2CC(=O)N21 RBKMMJSQKNKNEV-RITPCOANSA-N 0.000 claims description 2
- 239000011149 active material Substances 0.000 claims 4
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 31
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229960003342 pivampicillin Drugs 0.000 description 12
- 239000008187 granular material Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- UHPXMYLONAGUPC-WKLLBTDKSA-N pivmecillinam hydrochloride Chemical compound [H+].[Cl-].N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CN1CCCCCC1 UHPXMYLONAGUPC-WKLLBTDKSA-N 0.000 description 7
- 229940037380 pivmecillinam hydrochloride Drugs 0.000 description 7
- 229940024554 amdinocillin Drugs 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- NPGNOVNWUSPMDP-UTEPHESZSA-N chembl1650818 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=C\N1CCCCCC1 NPGNOVNWUSPMDP-UTEPHESZSA-N 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229960004212 pivmecillinam Drugs 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960004632 pivampicillin hydrochloride Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7932902 | 1979-09-21 | ||
| GB7932902 | 1979-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8005252A true NL8005252A (nl) | 1981-03-24 |
Family
ID=10508005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8005252A NL8005252A (nl) | 1979-09-21 | 1980-09-19 | Dubbellaagstablet. |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | AT371711B (de) |
| AU (1) | AU532764B2 (de) |
| DE (1) | DE3035509A1 (de) |
| FR (1) | FR2465479A1 (de) |
| IT (1) | IT1209809B (de) |
| NL (1) | NL8005252A (de) |
| NZ (1) | NZ194785A (de) |
| SE (1) | SE444887B (de) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1405866A (en) * | 1919-12-12 | 1922-02-07 | Frank X Ratkovic | Planting machine |
| GB1405886A (en) * | 1971-11-01 | 1975-09-10 | Astra Laekemedel Ab | Synergistic compositions comprising penicillin and cephalosporin antibiotics |
| GB1478598A (en) * | 1974-05-17 | 1977-07-06 | Leo Pharm Prod Ltd | Antibiotic mixture |
-
1980
- 1980-08-27 NZ NZ194785A patent/NZ194785A/xx unknown
- 1980-09-15 AT AT0461480A patent/AT371711B/de not_active IP Right Cessation
- 1980-09-19 IT IT8068456A patent/IT1209809B/it active
- 1980-09-19 FR FR8020247A patent/FR2465479A1/fr active Granted
- 1980-09-19 AU AU62564/80A patent/AU532764B2/en not_active Ceased
- 1980-09-19 NL NL8005252A patent/NL8005252A/nl not_active Application Discontinuation
- 1980-09-19 SE SE8006592A patent/SE444887B/sv not_active IP Right Cessation
- 1980-09-19 DE DE19803035509 patent/DE3035509A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SE444887B (sv) | 1986-05-20 |
| AU532764B2 (en) | 1983-10-13 |
| IT8068456A0 (it) | 1980-09-19 |
| AU6256480A (en) | 1981-04-09 |
| AT371711B (de) | 1983-07-25 |
| ATA461480A (de) | 1982-12-15 |
| FR2465479B1 (de) | 1984-11-02 |
| IT1209809B (it) | 1989-08-30 |
| DE3035509A1 (de) | 1981-04-09 |
| NZ194785A (en) | 1983-05-31 |
| SE8006592L (sv) | 1981-03-22 |
| FR2465479A1 (fr) | 1981-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005249467B2 (en) | Coated tablet formulation and method | |
| CA2720450C (en) | New formulations, tablets comprising such formulations, their use and process for their preparation | |
| JP2774037B2 (ja) | ＨＭＧ−ＣｏＡリダクターゼ抑制活性を有する化合物を含んでなる安定化された製薬学的組成物 | |
| WO2013179307A2 (en) | Stabilized pharmaceutical compositions of saxagliptin | |
| CA2809509C (en) | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease | |
| EP2654736B1 (de) | Neuartige pharmazeutische zusammensetzung | |
| EA030999B1 (ru) | Применение фармацевтической композиции, включающей ингибитор дпп-4 и гидрохлорид метформина | |
| HUT76335A (en) | Polymer coated tablet comprising amoxycillin and clavulanate | |
| BG61796B1 (bg) | Орално приложими лекарствени форми, съдържащи пантопразол | |
| JPH11508578A (ja) | 徐放性可逆性プロトンポンプ抑制剤を有する経口医薬品 | |
| HU202102B (en) | Process for producing oral pharmaceutical compositions with controlled release of the active components | |
| EP2468361B1 (de) | Vildaglitptin-Formulierungen | |
| EP2854773B1 (de) | Pharmazeutische zusammensetzung von entecavir und verfahren zur herstellung | |
| CA2256751C (en) | Coated trimebutine maleate tablet | |
| US20050053669A1 (en) | Administration form for the oral application of poorly soluble acidic and amphorteric drugs | |
| GB2058565A (en) | Layer tablets | |
| EP2468256B1 (de) | Kombinationen aus Vildagliptin und Glimepirid | |
| NL8005252A (nl) | Dubbellaagstablet. | |
| EP1641440B1 (de) | Tablette enthaltend fluvastatin und calciumcarmellose | |
| EP3277278B1 (de) | Kombinierte darreichungsform aus einem mu-opioidrezeptorantagonisten und einem opioid | |
| JPH11335302A (ja) | 安定な医薬組成物 | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| JPH0873345A (ja) | 医薬製剤 | |
| JPH0236571B2 (ja) | Jizokuseiseizai | |
| Reddy | Formulation and Evaluation of Bilayer Tablets of Ramipril as Immediate Layer and Propranolol Hydrochloride as Sustained Layer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |